A number of novel influenza drugs under development could hit US and European markets next winter, delivering more options for treatment and prevention. Among the potential therapies are Janssen's pimodivir, which interferes with genetic replication by targeting part of a gene found in most seasonal flu viruses, and Shionogi & Co. and Roche's baloxavir, which works by inhibiting an enzyme that the flu virus needs to replicate inside host cells.
Novel drugs targeting flu virus could arrive next winter
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.